Becton, Dickinson and Co. (BDX), or BD, comprises BD Medical and BD Lifesciences segments. BDX’s Lifesciences business generated revenues of ~$3.8 billion in fiscal 2016, ended September 30, 2016. The segment consists of three divisions: Preanalytical Systems, Diagnostic Systems, and Biosciences.
All of the company’s businesses have strong leadership positions, registering strong YoY (year-over-year) growth. For a brief overview of BDX’s recent earnings results, please read How Did Becton Dickinson Perform in Fiscal 3Q16?
BD Lifesciences segment’s core focus areas
Becton, Dickinson and Co. (BDX) has identified some key focus areas that have significant growth potential. In the Preanalytical Systems division, BD has a leadership position in the sample management business and is focused on its further expansion through innovation.
In the Diagnostics and Microbiology business, BD is focused on the total lab automation of its Keistra platform–powered traditional microbiology infectious disease lab, which could lead the transition to the molecular diagnostics lab.
Flow cytometry is another high-growth business area under BD’s Biosciences division, where the company aims to expand into new markets through genomics and cell therapy tools.
Thermo Fisher Scientific (TMO), Illumina (ILMN), and Abbott Laboratories (ABT) are some of the closest competitors of BD in these market spaces. Investors can gain exposure to the BDX’s growth potential by investing in the SPDR S&P 500 ETF (SPY). SPY holds ~0.18% of its total portfolio in BD.
Under the Preanalytical segment, BDX recently launched Barricor and Ultratouch Push Button, which could improve lab efficiency and the patient experience. The company states that these launches are its most differentiated product launches in this business in a decade.